Details of the Drug
General Information of Drug (ID: DMIHFQY)
Drug Name |
HOMOAROMOLINE
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Homoaromoline; (+)-Homoaromoline; Thalrugosamine; 6,6',12'-Trimethoxy-2,2'-dimethyloxyacanthan-7-ol; 17132-74-0; NSC 251213; CHEMBL509855; NSC-251213; Oxyacanthan-7-ol, 6,6',12'-trimethoxy-2,2'-dimethyl-; (+)-Thalrugosamine; Homothalicrine; Limacusine (R,S); ( )-Thalrugosamine; Homothalicrine (7CI); SCHEMBL2991819; AC1Q58F3; AC1L410X; DTXSID90169059; NSC251213; BDBM50241641; LS-75888; Oxyacanthan-7-ol,6',12'-trimethoxy-2,2'-dimethyl-; Oxyacanthan-7-ol, 6,6',12'-trimethoxy-2,2'-dimethyl- (9CI)
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 608.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 6.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||